Breakpoints cover image

#75 – Breakpoints Talks Breakpoints: Aminoglycosides

Breakpoints

00:00

Pseudomonas and Aminoglycosides: A Comparison

Pip Tengza: I think what happened with pseudo maybe arguably is even more controversial. The changes with Pseudomonas are more drastic and really clinicians need to know what's up with this, he says. "The take home from the M100 for 2023 from CLS side that will most blow people's minds," Pang added.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app